A study projects the global adoption of 6-month drug-resistant TB (DR-TB) regimens by 2026. The WHO recommends the BPaL/M regimen, which includes pretomanid, bedaquiline, and linezolid, as a shorter alternative to longer treatments. The study, based on interviews with national TB program officials in 13 countries, estimates that by 2026, BPaLM will treat 126,792 patients, BPaL will treat 43,716 patients, and a 9-month all-oral bedaquiline-based regimen will treat 13,119 patients. The longer all-oral regimen is projected to treat 19,262 patients, and individualized regimens will treat 15,344 patients. The BPaL/M regimen is expected to be used by 78% of DR-TB patients by 2026. The study highlights the need for global health stakeholders to plan and budget for DR-TB interventions, as well as to ensure access to new treatments. The study also notes that the use of bedaquiline, linezolid, and pretomanid is expected to increase significantly, with bedaquiline projected to be used by 202,920 patients by 2026, linezolid by 188,503 patients, and pretomanid by 170,000 patients. The study emphasizes the importance of scaling up drug susceptibility testing, improving access to new treatments, and engaging communities to ensure the successful implementation of these regimens. The findings suggest that the global adoption of shorter DR-TB regimens will continue to grow, with the BPaL/M regimen playing a key role in reducing the burden of DR-TB.A study projects the global adoption of 6-month drug-resistant TB (DR-TB) regimens by 2026. The WHO recommends the BPaL/M regimen, which includes pretomanid, bedaquiline, and linezolid, as a shorter alternative to longer treatments. The study, based on interviews with national TB program officials in 13 countries, estimates that by 2026, BPaLM will treat 126,792 patients, BPaL will treat 43,716 patients, and a 9-month all-oral bedaquiline-based regimen will treat 13,119 patients. The longer all-oral regimen is projected to treat 19,262 patients, and individualized regimens will treat 15,344 patients. The BPaL/M regimen is expected to be used by 78% of DR-TB patients by 2026. The study highlights the need for global health stakeholders to plan and budget for DR-TB interventions, as well as to ensure access to new treatments. The study also notes that the use of bedaquiline, linezolid, and pretomanid is expected to increase significantly, with bedaquiline projected to be used by 202,920 patients by 2026, linezolid by 188,503 patients, and pretomanid by 170,000 patients. The study emphasizes the importance of scaling up drug susceptibility testing, improving access to new treatments, and engaging communities to ensure the successful implementation of these regimens. The findings suggest that the global adoption of shorter DR-TB regimens will continue to grow, with the BPaL/M regimen playing a key role in reducing the burden of DR-TB.